APROVASC FILM COATED TABLET 150MG/5MG

TABLET, FILM COATED

**DOSAGE AND METHOD OF ADMINISTRATION:** The usual initial and maintenance dose of Aprovasc® is one tablet per day. Aprovasc® can be administered with or without food. Aprovasc® should be administered in patients whose blood pressure is not adequately controlled on monotherapy with irbesartan or amlodipine or for continuation of therapy for patients receiving irbesartan and amlodipine as separate tablets. Dose should be determined on a case-by-case basis, based on patient response to therapy with the individual components and the desired antihypertensive response. The maximum recommended dose with Aprovasc® is 300 mg/10 mg per day. Treatment should be adjusted based on blood pressure response. _Pediatric patients:_ The safety and efficacy of Aprovasc® has not been established in this population. _Elderly patients and patients with impaired renal function:_ In general, no dosage reduction is necessary in elderly patients or patients with impaired renal function (regardless of the degree of impairment). _Patients with impaired hepatic function:_ As the medicinal product contains amlodipine, Aprovasc® should be administered with caution in these patients (see Warnings – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Medicinal product for oral administration